Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients

• Published in: British journal of cancer 2007-11, Vol.97 (10), p.1329-1332
• Main Authors: Atzpodien, J, Terfloth, K, Fluck, M, Reitz, M
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Busulfan - administration & dosage; Busulfan - adverse effects; Busulfan - analogs & derivatives; Cancer Research; Cisplatin - administration & dosage; Cisplatin - adverse effects; Clinical Study; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Dermatology; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Epidemiology; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Medical sciences; Melanoma - drug therapy; Melanoma - secondary; Middle Aged; Molecular Medicine; Neoplasm Staging; Neoplasms, Unknown Primary - drug therapy; Oncology; Recurrence; Remission Induction; Skin Neoplasms - drug therapy; Survival Rate; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6604045

To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40 mg m −2 intravenous (i.v.) cisplatin, 1000 mg m −2 i.v. gemcitabine, and 2500 mg m −2 i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with prolonged but limited survival.